Showing results (251-260 of 280) with videos related to

Sort By:
Pageof 28
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)J W Holch, S Held, S Stintzing, et al.
Archives of Orthopaedic and Trauma Surgery|May 25, 2002
Side-effects of extracorporeal shock wave therapy (ESWT) in the treatment of tennis elbowM Haake, I R Böddeker, T Decker, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2025
Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosisLaila M Rad, Kevin R Hughes, Sydney N Wheeler, et al.
Physical Review Letters|April 14, 2020
Erratum: Delayed Onset of Nonthermal Melting in Single-Crystal Silicon Pumped with Hard X Rays [Phys. Rev. Lett. 120, 265701 (2018)]T Pardini, J Alameda, A Aquila, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2023
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trialN Harbeck, P A Fasching, R Wuerstlein, et al.
Physical Review Letters|July 14, 2018
Delayed Onset of Nonthermal Melting in Single-Crystal Silicon Pumped with Hard X RaysT Pardini, J Alameda, A Aquila, et al.
ESMO Open|August 22, 2024
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFIA H S Alig, D P Modest, S Stintzing, et al.
Cancer Research|October 31, 2019
Metastatic Conditioning of Myeloid Cells at a Subcutaneous Synthetic Niche Reflects Disease Progression and Predicts Therapeutic OutcomesRobert S Oakes, Grace G Bushnell, Sophia M Orbach, et al.
ESMO Open|November 10, 2022
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)M Schmidt, K Lübbe, T Decker, et al.
ESMO Open|June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA studyM Schmidt, M Thill, J Rey, et al.
Pageof 28